CME
Expert recommendations for when and how to augment or switch treatment for MDD.
Physicians: Maximum of 0.25 AMA PRA Category 1 Credit™
Released: April 17, 2020
Expiration: April 16, 2021
Share
Leslie Citrome, MD, MPH
Clinical Professor
Department of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York
Christoph U. Correll, MD
Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
New York, New York
Professor and Chair
Department of Child and Adolescent Psychiatry
Charité University Medicine
Berlin, Germany
Rakesh Jain, MD, MPH
Clinical Professor
Department of Psychiatry
Texas Tech Health Sciences Center, School of Medicine
Midland, Texas
Roger McIntyre, MD, FRCPC
Professor of Psychiatry and Pharmacology
University of Toronto, Canada
Chairman and Executive Director, Brain and Cognition Discovery Foundation
Toronto, Canada
Board Chair, Depression and Bipolar Support Alliance
Board of Directors
Chicago, Illinois
Michael E. Thase, MD
Professor of Psychiatry
Department of Psychiatry
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
Provided by Clinical Care Options, LLC
Supported by an educational grant from
Otsuka and Lundbeck Alliance
This activity is intended primarily for psychiatrists and primary care physicians who care for patients with MDD.
Upon completion of this activity, participants should be able to:
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Primary Author
Leslie Citrome, MD, MPH
Clinical Professor
Department of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York
Leslie Citrome, MD, MPH, Acadia, Alkermes, Allergan, Avanir, BioXcel, Eisai, Impel, Indivior, Intra-Cellular Therapies, Janssen, Lundbeck, Luye, Merck, Neurocrine, Noven, Osmotica, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, Teva, and Vanda; has served on speaker bureaus for Acadia, Alkermes, Allergan, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, and Teva; and has ownership interest in Bristol-Myers Squibb, Johnson & Johnson, Lilly, Merck, and Pfizer.
Christoph U. Correll, MD
Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
New York, New York
Professor and Chair
Department of Child and Adolescent Psychiatry
Charité University Medicine
Berlin, Germany
Christoph U. Correll, MD, has disclosed that he has received funds for research support from Janssen/Johnson & Johnson and Takeda; consulting fees from Alkermes, Allergan, Angelini, Gedeon Richter, Gerson Lehrman Group, IntraCellular Therapies, Janssen/Johnson & Johnson, LB Pharma, Lundbeck, MedAvante-ProPhase, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva; fees for non-CME/CE services from Alkermes, Allergan, Angelini, Gedeon Richter, Janssen/Johnson & Johnson, Lundbeck, MedAvante-ProPhase, Otsuka, Pfizer, Recordati, Sumitomo Dainippon, Sunovion, and Takeda.
Rakesh Jain, MD, MPH
Clinical Professor
Department of Psychiatry
Texas Tech Health Sciences Center, School of Medicine
Midland, Texas
Rakesh Jain, MD, MPH, has disclosed that he has received consulting fees from Acadia, Alfasigma, Alkermes, Allergan, Eisai, Evidera, Impel, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine, Osmotica, Otsuka, Pamlab, Pfizer, Shire, Sunovion, Supernus, Takeda and Teva; fees from non-CME/CE services from Alkermes, Allergan, Ironshore Pharmaceuticals, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine, Otsuka, Pamlab, Pfizer, Shire, Sunovion, Takeda, Teva and Tris Pharmaceuticals; and funds for research support from Allergan, Lilly, Lundbeck, Otsuka, Pfizer, Shire, and Takeda; and that his spouse/partner has received consulting fees from Lilly, Otsuka, Pamlab, and Sunovion and fees for non-CME/CE services from Lilly.
Roger McIntyre, MD, FRCPC
Professor of Psychiatry and Pharmacology
University of Toronto, Canada
Chairman and Executive Director, Brain and Cognition Discovery Foundation
Toronto, Canada
Board Chair, Depression and Bipolar Support Alliance
Board of Directors
Chicago, Illinois
Roger McIntyre, MD, FRCPC, has disclosed that he has received consulting fees and fees for non-CME/CE services from Allergan, Janssen, Lundbeck, Minerva, Neurocrine, Otsuka, Pfizer, Purdue, Shire, Sunovion, and Takeda.
Michael E. Thase, MD
Professor of Psychiatry
Department of Psychiatry
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
Michael E. Thase, MD, has disclosed that he has received funds for research support from Acadia, Allergan, Axsome, Intracellular, Johnson & Johnson, Otsuka, and Takeda and consulting fees from Acadia, Akili, Alkermes, Allergan, H. Lundbeck, Jazz, Johnson & Johnson, Merck, Otsuka, and Pfizer.
Staff
Anne Roc, PhD
Director, Scientific Services
Anne Roc, PhD, has no relevant conflicts of interest to report.
Zachary Schwartz, MSc, ELS
Scientific Director
Zachary Schwartz, MSc, has no relevant conflicts of interest to report.
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 17, 2020, through April 16, 2021:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Enter patient details and submit case.
4. Review the patient case online or printed out.
5. Submit answers to the Clinical Implications questions and evaluation questions online.
You must respond to all Clinical Implications and evaluation questions to receive credit. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Program Medium
This program has been made available online.
The goal of this activity is to improve the learner’s competence in selecting treatment augmentation modalities (eg, dosage changes, antidepressant switching, adding atypical antipsychotic) for patients with MDD who respond suboptimally to antidepressant therapy.